Related Experiment Video
Updated: Jun 16, 2026

Conducting Respiratory Oscillometry in an Outpatient Setting
Published on: April 8, 2022
Assessing the Reduction of Recurrent Admissions Using OM-85 for the Treatment of Preschool Wheeze (ARROW): Protocol
Jessica C Costa-Pinto1,2,3, Marisa van Arragon4,5, Katherine J Lee6,7
1Deakin University, Geelong, Victoria, Australia.
Insights
This study investigates OM-85, a bacterial lysate, for preventing hospital readmissions in children with preschool wheeze. The ARROW trial assesses its efficacy in reducing recurrent wheezing illnesses and improving health outcomes.
Area of Science:
- Pediatric Pulmonology
- Immunology
- Clinical Trials
Background:
- Acute wheezing illnesses are a leading cause of hospital admissions in preschool children.
- High readmission rates necessitate novel preventive strategies.
- OM-85, a bacterial lysate, shows potential in modulating immune responses and reducing airway inflammation.
Purpose of the Study:
- To determine the efficacy of OM-85 in preventing hospital readmissions in children with preschool wheeze.
- To evaluate OM-85's impact on the frequency and duration of wheezing episodes.
- To assess the cost-effectiveness of using OM-85 for preschool wheeze management.
Main Methods:
- A decentralized, Phase 3 randomized, double-blind, placebo-controlled trial (ARROW).
- Recruitment of 870 children aged 1 to <6 years across over 40 hospitals in Australia and New Zealand.
- Daily administration of 3.5 mg OM-85 or placebo for 10 days each month over 12 months, with remote and in-person follow-up.
Main Results:
- Primary outcome: hospital admission due to acute wheezing illness during the 12-month treatment period.
- Secondary outcomes: frequency and duration of wheeze episodes, cost-effectiveness.
- Trial registered under ACTRN12620001370998.
Conclusions:
- The ARROW trial will provide crucial data on OM-85's effectiveness in managing preschool wheeze.
- Findings may lead to new preventive strategies, reducing hospitalizations and healthcare costs.
- Results will be disseminated through peer-reviewed international journals.
Aims:
Acute wheezing illnesses are among the most common reasons preschool-aged children are admitted to hospital. Readmission rates are high, and novel preventive strategies are required. OM-85 is an orally administered bacterial lysate that stimulates anti-viral immune responses and reduces excessive airway inflammation associated with wheezing episodes. The aim of the Assessing the Reduction of Recurrent admissions using OM-85 for the treatment of preschool Wheeze (ARROW) trial is to determine the efficacy of OM-85 in preventing hospital readmissions in children admitted to hospital with preschool wheeze. The primary outcome is hospital admission due to an acute wheezing illness during the 12-month treatment period. Secondary outcomes include the frequency and duration of wheeze episodes and the cost-effectiveness of the intervention.
Methods:
ARROW is a decentralised, Phase 3 randomised, double-blind, placebo-controlled trial. We aim to recruit and follow-up 870 children aged 1 to < 6 years. Participants are randomised to 3.5 mg of OM-85 or placebo daily for the first 10 days of every month, for 12 months. Health professionals from over 40 hospitals participating in the Children's Inpatient Research Collaboration of Australia and New Zealand (CIRCAN) invite families to the ARROW trial. The ARROW central team organises enrolment, randomisation, medication distribution, and follow-up, conducting these activities entirely remotely in Australia and both remotely and in-person in New Zealand.
Ethics And Dissemination:
ARROW received ethics approval from The Royal Children's Hospital Human Research Ethics Committee in Australia and the Health and Disability Ethics Committee in New Zealand. Findings will be published in peer-reviewed international journals.
Trial Registration:
ANZCTR: ACTRN12620001370998 (Registered on 21 December 2020).
Related Concept Videos
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
COPD: Management Using Bronchodilators and Corticosteroids
Assessment of Respiration
Subjective Assessment: Nurses interview the patient to gather information directly during the subjective assessment. It includes questions about the individual's medical history, medications, and symptoms, focusing on past respiratory conditions like asthma or COPD,...
Asthma III: Clinical Manifestations
